C M Lockwood
Overview
Explore the profile of C M Lockwood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
3333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacKinnon D, Lockwood C, Brown C, Wang W, Hoffman J
Clin Trials
. 2007 Oct;
4(5):499-513.
PMID: 17942466
Background: An intermediate endpoint is hypothesized to be in the middle of the causal sequence relating an independent variable to a dependent variable. The intermediate variable is also called a...
2.
Lockwood C, Hale G, Waldman H, Jayne D
Rheumatology (Oxford)
. 2003 Sep;
42(12):1539-44.
PMID: 12949252
Objective: Behçet's disease (BD) is a multisystem vasculopathy of unknown cause with variable clinical presentation and the outcome of current treatments is often unsatisfactory. There is evidence for T-cell autoreactivity...
3.
Huang Z, Lockwood C
Chin Med J (Engl)
. 2002 Jan;
114(7):760-3.
PMID: 11780345
Objective: To map the epitopes on Wegener's granulomatosis autoantigen proteinase 3. Methods: Antigenicity of proteinase 3 was studied with Western blot analysis in which proteinase 3 was prepared under reducing...
4.
MacKinnon D, Krull J, Lockwood C
Prev Sci
. 2001 Aug;
1(4):173-81.
PMID: 11523746
This paper describes the statistical similarities among mediation, confounding, and suppression. Each is quantified by measuring the change in the relationship between an independent and a dependent variable after adding...
5.
Audrain M, Sesboue R, Baranger T, Elliott J, Testa A, Martin J, et al.
Nephrol Dial Transplant
. 2001 Feb;
16(1):39-44.
PMID: 11208991
Background: ANCA are autoantibodies directed against polymorphonuclear cell antigens, mainly proteinase 3 (PR3) and myeloperoxidase (MPO), which are implicated in the pathogenesis of small-vessel necrotizing vasculitis. Alpha1-antitrypsin is the main...
6.
Jayne D, Chapel H, Adu D, Misbah S, ODonoghue D, Scott D, et al.
QJM
. 2000 Jun;
93(7):433-9.
PMID: 10874052
Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate...
7.
Watts R, SCOTT D, Pusey C, Lockwood C
Rheumatology (Oxford)
. 2000 May;
39(3):229-32.
PMID: 10788527
No abstract available.
8.
Lockwood C, Elliott J, Brettman L, Hale G, REBELLO P, Frewin M, et al.
Clin Immunol
. 1999 Oct;
93(2):93-106.
PMID: 10527685
Functional inactivation of leukocyte adhesion molecules has been used to intervene in the development of tissue injury in experimental models of postperfusion infarction as well as autoimmune inflammation. We investigated...
9.
Mahadeva R, Dunn A, Westerbeek R, Sharples L, Whitehouse D, Carroll N, et al.
Clin Exp Immunol
. 1999 Sep;
117(3):561-7.
PMID: 10469063
Persistent infection with Pseudomonas aeruginosa and inflammatory mechanisms play an important role in cystic fibrosis (CF) lung disease. ANCA against BPI, a potent host defence protein with anti-bacterial and anti-endotoxin...
10.
Dunn A, Walmsley R, Dedrick R, Wakefield A, Lockwood C
J Infect
. 1999 Sep;
39(1):81-7.
PMID: 10468134
Objectives: to identify the region of bactericidal/permeability-increasing protein (BPI) recognized by anti-BPI ANCA. Methods: sera from 140 patients with a variety of clinical diagnoses (20 systemic vasculitis, 12 cystic fibrosis,...